Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.
In a double-blind, crossover study, 13 fluoxetine-treated patients with obsessive-compulsive disorder were given adjuvant buspirone and placebo for 4 weeks each. There were no significant differences between buspirone and placebo in obsessive-compulsive, depressive, or anxiety symptoms.
Grady
T A
TA
Department of Psychiatry, Duke University Medical Center, Durham, NC 27710.
Pigott
T A
TA
L'Heureux
F
F
Hill
J L
JL
Bernstein
S E
SE
Murphy
D L
DL
D000328:Adult; D001008:Anxiety Disorders / Q000188:drug therapy / Q000523:psychology; D002065:Buspirone / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D010919:Placebos
D010919:Placebos; D005473:Fluoxetine; D002065:Buspirone